Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aumolertinib”

56 trials

Showing 20 of 56 results

Large-scale testing (Phase 3)Looking for participantsNCT07183189
What this trial is testing

SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 576
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06463171
What this trial is testing

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Shanghai Pulmonary Hospital, Shanghai, China 60
Testing effectiveness (Phase 2)UnknownNCT04922138
What this trial is testing

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Who this might be right for
Lung Cancer
Baohui Han 104
Testing effectiveness (Phase 2)Looking for participantsNCT06300424
What this trial is testing

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Guangdong Provincial People's Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05503888
What this trial is testing

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Who this might be right for
Relapsed or Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 160
Testing effectiveness (Phase 2)UnknownNCT04455594
What this trial is testing

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIA
The First Affiliated Hospital of Guangzhou Medical University 168
Testing effectiveness (Phase 2)UnknownNCT05946460
What this trial is testing

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Who this might be right for
Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 22
Large-scale testing (Phase 3)Active Not RecruitingNCT04687241
What this trial is testing

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 192
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Early research (Phase 1)UnknownNCT05826483
What this trial is testing

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Who this might be right for
Malignant Tumor of LungPoor Performance Status
Guangzhou Institute of Respiratory Disease 20
Not applicableLooking for participantsNCT06102928
What this trial is testing

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University 30
Testing effectiveness (Phase 2)UnknownNCT04785742
What this trial is testing

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Who this might be right for
Safety of Almonertinib
Sun Yat-sen University 40
Testing effectiveness (Phase 2)WithdrawnNCT06227897
What this trial is testing

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Looking for participantsNCT06951464
What this trial is testing

BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06947811
What this trial is testing

Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Sun Yat-sen University 71
Large-scale testing (Phase 3)Enrolling By InvitationNCT04762459
What this trial is testing

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Who this might be right for
Non-small Cell Lung Carcinoma
Chinese Academy of Medical Sciences 606
Early research (Phase 1)UnknownNCT05430386
What this trial is testing

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 174
Testing effectiveness (Phase 2)UnknownNCT05810350
What this trial is testing

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Who this might be right for
Non-small Cell Lung Cancer
Three Gorges Hospital of Chongqing University 40
Testing effectiveness (Phase 2)UnknownNCT04553887
What this trial is testing

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 53
Testing effectiveness (Phase 2)UnknownNCT04952168
What this trial is testing

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Who this might be right for
NSCLC, Stage III
Yuan Chen 26
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation